Literature DB >> 7824102

Alterations of GABAergic neurons in the basal ganglia of patients with progressive supranuclear palsy: an in situ hybridization study of GAD67 messenger RNA.

R Levy1, M Ruberg, M T Herrero, J Villares, F Javoy-Agid, Y Agid, E C Hirsch.   

Abstract

We analyzed postmortem GABAergic neurons in the basal ganglia of three patients with progressive supranuclear palsy (PSP) and four matched controls by means of glutamic acid decarboxylase (M(r) 67,000 [GAD67]) mRNA in situ hybridization. In PSP, we found a 50 to 60% decrease in the number of neurons expressing GAD67 mRNA in the caudate nucleus, ventral striatum, and the external and internal pallidum. The expression of GAD67 mRNA per neuron was reduced in the caudate nucleus and putamen (-43%), the ventral striatum (-55%), and the external and internal pallidum (-59% and -68%). Our data indicate that striatal and pallidal GABAergic neurotransmission is markedly reduced in PSP and we suggest that this alteration may account for the motor and cognitive symptoms observed in PSP. Furthermore, the destruction of the basal ganglia output systems may explain the lack of responsiveness to L-dopa therapy of PSP patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7824102     DOI: 10.1212/wnl.45.1.127

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  14 in total

Review 1.  Progressive supranuclear palsy.

Authors:  H U Rehman
Journal:  Postgrad Med J       Date:  2000-06       Impact factor: 2.401

2.  Current and future treatments in progressive supranuclear palsy.

Authors:  Irene van Balken; Irene Litvan
Journal:  Curr Treat Options Neurol       Date:  2006-05       Impact factor: 3.598

3.  Morphometric analysis of subcortical structures in progressive supranuclear palsy: In vivo evidence of neostriatal and mesencephalic atrophy.

Authors:  Jeffrey C L Looi; Matthew D Macfarlane; Mark Walterfang; Martin Styner; Dennis Velakoulis; Jimmy Lätt; Danielle van Westen; Christer Nilsson
Journal:  Psychiatry Res       Date:  2011-09-06       Impact factor: 3.222

4.  Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease.

Authors:  Jean-Christophe Corvol; Marie-Paule Muriel; Emmanuel Valjent; Jean Féger; Naïma Hanoun; Jean-Antoine Girault; Etienne C Hirsch; Denis Hervé
Journal:  J Neurosci       Date:  2004-08-04       Impact factor: 6.167

Review 5.  Clinical trials: past, current, and future for atypical Parkinsonian syndromes.

Authors:  Richard M Tsai; Adam L Boxer
Journal:  Semin Neurol       Date:  2014-06-25       Impact factor: 3.420

Review 6.  A Review of Treatment Options for Progressive Supranuclear Palsy.

Authors:  Maria Stamelou; Günter Höglinger
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

7.  The basal ganglia cholinergic neurochemistry of progressive supranuclear palsy and other neurodegenerative diseases.

Authors:  N M Warren; M A Piggott; A J Lees; D J Burn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-12-18       Impact factor: 10.154

Review 8.  Genetics Underlying Atypical Parkinsonism and Related Neurodegenerative Disorders.

Authors:  Sonja W Scholz; Jose Bras
Journal:  Int J Mol Sci       Date:  2015-10-16       Impact factor: 5.923

9.  Trial of Zolpidem, Eszopiclone, and Other GABA Agonists in a Patient with Progressive Supranuclear Palsy.

Authors:  Andrew Young Chang; Erica Weirich
Journal:  Case Rep Med       Date:  2014-09-16

10.  Zolpidem in progressive supranuclear palsy.

Authors:  Sandip K Dash
Journal:  Case Rep Neurol Med       Date:  2013-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.